Paper Details

  1. Home
  2. Paper Details

Successful treatment of paediatric generalized pustular psoriasis with secukinumab: a case series.

Author: AlbelaHenrietta, BegumSabeera, LeongKin Fon

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Generalized Pustular Psoriasis (GPP) is a rare and severe form of psoriasis. Secukinumab, an anti-IL-17A monoclonal antibody, has shown efficacy in adults with GPP. This case series reports on four pediatric patients with GPP treated with secukinumab. All patients achieved marked clearance and reduction in GPPASI scores within 48 hours of the first injection. These findings suggest secukinumab may be effective for pediatric GPP.
Paper Details　
Original Abstract of the Article :
Generalized Pustular Psoriasis (GPP) is a rare, severe, life-threatening form of psoriasis and accounts for up to 13.1% of all childhood psoriasis. Common first-line systemic treatment for pediatric patients with GPP include oral acitretin, cyclosporin and methotrexate which have varying efficacy an...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1080/09546634.2021.1899111

データ提供：米国国立医学図書館（NLM）

Secukinumab: A Hopeful Light in the Desert of Pustular Psoriasis

Generalized Pustular Psoriasis (GPP) is a severe, potentially life-threatening skin condition, particularly challenging for children. This study focuses on the promising use of secukinumab, a new medication, to treat GPP in children.

A New Oasis in Psoriasis Treatment: Secukinumab's Impact on GPP

This study examined four pediatric patients with GPP who were treated with secukinumab. The results were remarkable – all four patients experienced significant improvement in their skin condition, with a dramatic reduction in symptoms within just 48 hours of receiving the medication. This research provides exciting evidence for the potential of secukinumab to revolutionize GPP treatment for children.

A Brighter Future for Children: Secukinumab's Role in GPP Management

Secukinumab offers a new hope for children suffering from GPP, providing a potentially safer and more effective treatment option than existing therapies. This discovery is like finding a lush oasis in a scorching desert, offering relief and healing to those struggling with this debilitating disease.

Dr.Camel's Conclusion

Secukinumab represents a promising new treatment for pediatric GPP, potentially bringing much-needed relief and hope to families dealing with this challenging condition. It's like finding a refreshing spring in the middle of the desert, bringing life and vitality to those who have been parched for so long.

Date :
  1. Date Completed 2022-08-25
  2. Date Revised 2022-09-01
Further Info :

Pubmed ID

33706651

DOI: Digital Object Identifier

10.1080/09546634.2021.1899111

Related Literature

Article Analysis
・Side Effects of secukinumab injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.